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Abstract
Syndecan-3 is one of the four members of the syndecan family of heparan
sulphate proteoglycans and has been shown to interact with numerous growth
factors via its heparan sulphate chains. The extracellular core proteins of
syndecan-1,-2 and -4 all possess adhesion regulatory motifs and we
hypothesized that syndecan-3 may also possess such characteristics. Here we
show that a bacterially expressed GST fusion protein consisting of the entire
mature syndecan-3 ectodomain has anti-angiogenic properties and acts via
modulating endothelial cell migration. This work identifies syndecan-3 as a
possible therapeutic target for anti-angiogenic therapy.
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Introduction
Angiogenesis is the process of new blood vessel formation from 
pre-existing vessels. This process is essential for embryonic devel-
opment but it is also a feature of pathologies such as cancer and 
chronic inflammation (reviewed in1). For angiogenesis to occur, 
the release of pro-angiogenic factors, which promote the transi-
tion of endothelial cells (ECs) from a quiescent to a proliferative 
and migratory phenotype, is required2–4. The best characterized 
pro-angiogenic molecules are: vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF) and platelet derived growth 
factor (PDGF) (reviewed in5). Angiogenesis represents an attractive 
target for the treatment of cancer, as during tumour development 
new blood vessels permeate the tumour mass and provide oxygen 
and nutrients to further enhance tumour growth. Therapies aimed 
at blocking angiogenesis have focused on targeting VEGF and its 
related receptors, however the prohibitive cost of such treatments 
and their side effects mean that there is still a need to discover new 
therapeutic anti-angiogenic targets4.
Syndecans are a four member family of transmembrane adhesion 
receptors with diverse expression and functionality6,7. Syndecan-3 
is the least well understood of the four family members. Like other 
syndecans, it possesses a short, highly conserved cytoplasmic domain, 
a single pass transmembrane domain and a large extracellular 
domain containing 6 glycosaminoglycan attachment sites which 
can be substituted by both heparan sulphate (HS) and chondroitin 
sulphate (CS). Syndecan-3 has the largest extracellular core protein 
of the syndecans and, in addition to the HS and CS modifications, 
the molecule possesses a number of potential sites for O-linked 
glycosylation resembling a mucin-rich domain which may affect 
both the structure and molecular interactions of syndecan-38,9.
Syndecan-3 Knock-Out mice, in common with other syndecan-KO 
animals, develop normally and only under conditions of challenge 
or insult are different phenotypes observed6. Syndecan-3 is mainly 
found in the nervous system and has been shown to be a co-receptor 
for a number of important growth factors, including Agouti related 
protein (AgRP), heparin binding growth associated molecule 
(HB-GAM), glial cell line derived growth factor (GDNF), neurturin 
(NRTN), artemin (PSPN) and NOTCH, via interactions with its HS 
chains10–14. Interactions with AgRP, an antagonist of melanocortin, 
lead to altered feeding behaviours in the syndecan-3 null mouse14,15. 
In addition, syndecan-3 deficiency leads to the mice exhibiting 
more addictive behaviours to opiates such as cocaine, and this 
occurs as a result of its interaction with GDNF16. Syndecan-3 is also 
expressed on satellite cells, adult skeletal muscle progenitors and 
has roles in the development of normal adult muscle13,17–19.
An important emerging feature of syndecans is that sequences 
contained within their extracellular core domains have biological 
activity which can influence cell adhesion and migratory responses20. 
Such domains have been identified in syndecan-1, 2 and -421. The 
syndecans can be divided into two subfamilies based on sequence 
homology: syndecan-1 and -3 and syndecans -2 and -422. Since 
regions of the syndecan-1 core protein are anti-angiogenic, we 
hypothesized that the core protein of syndecan-3 may exhibit simi-
lar properties23–25. In this study we demonstrate that the syndecan-3 
extracellular core protein is able to inhibit angiogenesis by reducing 
the migratory potential of endothelial cells and as such may be a 
candidate for use in anti-angiogenic therapy.
Materials and methods
Cell culture: Brain endothelial cells (bEND3.1) and skin endothe-
lial cells (sEND) were obtained from Health Protection Agency UK 
and were grown in DMEM (PAA, GE Healthcare) supplemented 
with 10% FBS, 2 mM l-glutamine, 1% non-essential amino acids, 
1 mM sodium pyruvate and 5 μM β-mercaptoethanol (all Invitrogen), 
at 37°C, 10% CO2.
Syndecan-3 GST fusion protein: The full length syndecan-3 cDNA 
was obtained from Source BioScience. The entire length of the 
mature syndecan-3 ectodomain (A45-L380) was amplified by PCR 
using the primers S3forEcoRI (ttaattgaattcgctcaacgctggcgcaatg) 
and S3revHindIII (ttaattaagcttctacagtatgctcttctgaggga) (Integrated 
DNA Technologies) and the resultant product was digested with 
EcoRI and HIndIII and ligated into the equivalent sites of pET41 
(Novagen) according to Manufacturer’s instructions. Plasmids were 
verified by sequencing and transformed into the BL21 strain of 
Escherichia coli (Novagen). S3ED protein was purified from bacte-
rial cultures which had reached an OD600 of 0.4 prior to the addition 
of 0.1 M Isopropyl β-D-1-thiogalactopyranoside (IPTG) and subse-
quent outgrowth for 4 hours. Affinity purification of both GST and 
S3ED was performed using glutathione-sepharose 4B (GE Health-
care) as described by the manufacturers.
Aortic ring assay: Angiogenic sprouts were induced from rat tho-
racic aortas according to the method of Nicosia and Ottinetti26. 
Briefly, aortas were dissected from cervically dislocated 180–200g 
12 male Wistar rats (Harlan Laboratories) and sliced into 0.5 mm 
sections and incubated overnight in serum free OptiMEM (Inv-
itrogen) at 37°C. Aortic rings were embedded in type I collagen 
(1 mg/ml) in E4 media (Invitrogen) containing either GST or S3ED 
in 48 well plates (Corning). Wells were supplemented with Opti-
MEM with 1% FBS and 10 ng/ml VEGF (R and D systems) and 
incubated at 37°C, 10% CO2. Angiogenic sprouts from rat aortas 
were counted after 4 days and 8 days respectively. Animals were 
housed and treated in Accordance with UK Home Office Regulations.
EC tubule formation assay: Endothelial cell microtubule formation 
was measured as follows: ECs (5 × 104) were seeded into 24 well 
plates coated with 150 μl of Matrigel (BD sciences) in the presence 
of either GST or S3ED. Using the Cell-IQ controlled environmental 
chamber (CM technologies), the plates were incubated at 37°C, 
10% CO2 and images were captured every 15 minutes for 16 hours.
Scratch wound migration assay: Confluent monolayers of bEND 
cells were scratched with a pipette tip, cells were then washed twice 
with PBS prior to the addition of growth medium supplemented 
with 0.5 μM of either GST or S3ED. Wounds were monitored 
by time lapse microscopy using an Olympus IX81 Microscope 
Hamamatsu Orca ER digital camera. Images were acquired every 
30 minutes and subsequently analysed using Adobe Photoshop. 
Cell speed was quantified by manually measuring the track of 
individual cells migrated for 9 hours (20 cells per conditions) using 
Adobe Photoshop, track lengths were then divided by the time to 
obtain cell speed.
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Cell proliferation assay: EC proliferation was measured using the 
CellTiter 96 AQueous Cell proliferation assay kit as described by 
the manufacturer (Promega). bEND (5 × 103/spot) cells were seeded 
in a 96-well plate (Corning) and incubated in the presence of 
0.5 μM either GST or S3ED.
Invasion assay: EC invasion assays through collagen matrices 
were performed in 24-well plates with trans-well inserts (Millipore; 
8 μm pore size, polyester (PET) membrane). Membranes were 
coated with 10 μl of Collagen Type I mixture (Millipore; 1 mg/ml 
in E4 medium) containing 0.5 μM GST or S3ED. sEND cells were 
seeded on the gel in a homogenous single cell suspension of 5 × 103 
cells/ insert in 200 μl of DMEM + 10% FBS; 1 ml of the same 
medium was added to the bottom well. Invasion was measured after 
6 hours after which time gels were removed with a cotton swab, the 
filter washed in PBS and stained with calcein (Invitrogen) and the 
number of cells attached to the filter was counted.
Results
In keeping with previous studies from our group and others in the 
field25,27–29, we set out to determine whether the extracellular core 
protein of syndecan-3 (S3ED) had any effect on cellular responses 
such as cell adhesion or migration and in particular on angiogenesis. 
To do this we generated a fusion protein consisting of the entire 
length of the syndecan-3 extracellular core protein (A45-L380) fused 
at the N-terminus to GST (S3ED). S3ED was expressed and puri-
fied from bacteria and therefore was not substituted with GAGs, or 
O-linked sugars, since bacteria lack the necessary transferases to 
perform these post-translational modifications (Figure 1).
In the aortic ring assay, angiogenic sprouts are formed from 
sections of rat aortas when embedded into a collagen I matrix 
(Figure 2a and b). Sprouting occurs in the absence of VEGF although 
a more robust response is observed when this growth factor is 
included in the medium (Figure 2c). We incorporated 0.5 μM of 
either GST or S3ED into the collagen I matrices to see if they 
affected sprout formation. Significantly fewer sprouts were observed 
in the presence of S3ED compared to either the untreated control or 
GST treated rings. This was true for both rings grown in the pres-
ence or in absence of VEGF (Figure 2c). We then demonstrated that 
this inhibition of angiogenesis is dose dependent; as little as 0.5 μM 
of S3ED had an inhibitory effect (Figure 3). Although 0.1 μM of 
S3ED also showed a statistically significant anti-angiogenic effect 
in this assay, we decided to use the higher dose (0.5 μM) for further 
experiments.  
Figure 1. Syndecan-3 and S3ED-GST structures. Diagrammatic 
representation of the syndecan-3 fusion protein (S3ED) used in this 
study. The entire length of the syndecan-3 extracellular core protein 
(A45-L380) was fused at the N-terminus to GST. 
Figure 2. S3ED inhibits sprout formation in the rat aortic ring assay. (a) Low magnification (bar=500 µm) of a rat aortic ring and (b) high 
magnification (bar=100 µm) image of an angiogenic sprout grown under control conditions. (c) S3ED inhibits angiogenic sprout formation 
from rat aortic rings. Rat aortic rings were seeded in Collagen I gels with 0.5 µM of either S3ED or GST in the presence or absence of VEGF. 
Data is the mean taken from rings from 3 different animals and error bars represent the SEM. One-way ANOVA with Bonferroni multiple 
comparisons was used to compare S3ED to relative UT control.
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Tubular network formation in response to matrigel is another measure 
of angiogenesis30. Brain endothelial cells form highly branched 
networks when seeded on matrigel and this was unaffected when 
GST was added to the culture medium (Figure 4a). In the presence 
of S3ED (0.5 μM) far fewer branch points were evident and the 
length of the microtubules was greatly reduced (Figure 4b and c; 
and Movie 1 and Movie 2). Together these data suggest that S3ED 
has anti-angiogenic properties.
Figure 3. The anti-angiogenic effect of S3ED is dose dependant. Rat aortic rings were embedded in Collagen I with the indicated 
concentrations of either GST or S3ED in the presence of VEGF. Angiogenic sprouts were counted 4 days after seeding. Data is from 5 rings per 
condition. One-way ANOVA with Bonferroni multiple comparisons was used to compare S3ED 0.5 µM to S3ED 0 µM considered as a control.
Figure 4. S3ED inhibits EC network formation in response to Matrigel. bEND3.1 cells were seeded on Matrigel in media containing GST 
or S3ED (0.5 µM) and micrographs were obtained after 16 hours (a). Tube length (b) and branch points (c) were calculated and both were 
reduced in the presence of S3ED. Error bar represents SEM. T-test was used to compare S3ED to GST control.
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Movies 1 and 2
2 Data Files
http://dx.doi.org/10.6084/m9.figshare.870448
The ectodomains of syndecan-1,-2 and -4 have all been shown to 
affect cell behaviour through interactions with integrins (for review 
see21). For example, the anti-angiogenic properties of syndecan-1 
have been demonstrated to occur through interactions with the αV 
sub-family25. Integrins are the major drivers of cell migration31,32 so 
we set out to determine whether the inhibitory properties of S3ED 
were due to effects on EC migration. Scratch wound cell migration 
assays revealed that S3ED significantly inhibited brain endothelial 
cell migration as compared to GST and untreated controls 
(Figure 5a). This was reflected in both percentage of wound closure 
and single cell speed measurements (Figure 5b and c). We further 
confirmed that S3ED inhibits EC migratory potential by using a 
3D culture system where we observed that S3ED, when incorpo-
rated into a collagen I matrix, inhibited endothelial cell invasion 
through the collagen (Figure 6a and b). Although we demonstrate 
that S3ED inhibits EC migration, it could be argued that these 
effects may also be associated with anti-proliferative effects of this 
protein. To test this we performed proliferation assays on brain 
ECs in the presence of S3ED or GST and observed no differ-
ences in the proliferation of these cells compared with controls 
(Figure 7).
Figure 5. S3ED inhibits brain EC migration. Scratch wounds were made to confluent monolayers of bEND3.1 cells and micrographs were 
captured after 9 hours clearly showing that wound closure is reduced in the presence of S3ED 0.5 µM (a). Scratch wound closure (b) and 
single cell speeds (c) were calculated. Single cell speed was calculated from 15–25 cells per condition. Error bars represent SD for (a) and 
SED for (b). One-way ANOVA with Bonferroni multiple comparisons was used to compare S3ED to relative UT control.
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Discussion
Here we show for the first time that the ectodomain of syndecan-3, 
like the other syndecan family members, has cell adhesion regulatory 
properties and acts as an inhibitor of angiogenesis. This strongly 
suggests that adhesion regulatory domains in syndecan extra-
cellular core domains exist in all four family members and also 
provides further insight as to how these molecules function. In-
terestingly, there is very little sequence homology between 
syndecan ectodomains32, and the adhesion regulatory motifs iden-
tified in syndecan-1,-2 and -4 are not present in S3ED. In addition, 
syndecan-3 is unique amongst the family since its core protein 
possesses a mucin-rich domain and it is likely that these O-linked 
sugars will also have a role in its molecular interactions. Although 
syndecan-3 expression is mostly associated with cells of the nerv-
ous system, it has also been found to be associated with cells related 
to maternal and foetal circulation33. Vascular defects in the syndecan-3 
null mouse have not been reported but the identification of S3ED 
as a regulator of angiogenesis suggests that this may be a fertile 
area for future research. This work identifies syndecan-3 as a 
potential therapeutic target in pathologies where angiogenesis is 
a feature.
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Figure 6. S3ED inhibits EC invasion into Collagen I. 5 × 103 sEND cells were seeded on 10 µl of Collagen I and were allowed to migrate 
for 6 hours. Numbers of transmigrated cells are shown in (a) and micrographs of transmigrated Calcein-labelled cells are in (b). Error bars 
represent SD. One-way ANOVA with Bonferroni multiple comparisons was used to compare S3ED to relative UT control.
Figure 7. EC proliferation is unaffected by either GST or S3ED. 
5 x 103 bEND 3.1 cells were incubated in the presence of 0.5 µM 
of either GST or S3ED. Error bars represent SD. One-way ANOVA 
with Bonferroni multiple comparisons was used to compare S3ED 
to relative UT control showing no statistically significant difference 
between the two at after 9 and 24 hours.
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it is of an acceptable scientific standard.
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This is a well conducted study which highlights an unforeseen role for the heparan sulphate proteoglycan
syndecan-3. Additionally, beyond the realms of this study, these data suggest more detailed knowledge
of the syndecan-3 expression profile is required.
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